PNH - Paroxysmal Nocturnal Hemoglobinuria
1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
NovelMed TherapeuticsNM8074
Longbio PharmaLP-005 Injection
Longbio PharmaLP-005 Injection
Clinical Trials (3)
Total enrollment: 136 patients across 3 trials
Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Start: Jun 2026Est. completion: Mar 20286 patients
Phase 2Not Yet Recruiting
Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis
Start: May 2026Est. completion: Mar 2027100 patients
Phase 2Not Yet Recruiting
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.
Start: Nov 2024Est. completion: Mar 202830 patients
Phase 2Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.